WINTON GROUP Ltd Purchases Shares of 17,810 IQVIA Holdings Inc. $IQV

WINTON GROUP Ltd purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the third quarter, HoldingsChannel.com reports. The fund purchased 17,810 shares of the medical research company’s stock, valued at approximately $3,383,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Alliancebernstein L.P. lifted its position in IQVIA by 0.6% during the 2nd quarter. Alliancebernstein L.P. now owns 3,555,929 shares of the medical research company’s stock worth $560,379,000 after acquiring an additional 19,573 shares during the period. Artisan Partners Limited Partnership boosted its holdings in shares of IQVIA by 4.9% in the 3rd quarter. Artisan Partners Limited Partnership now owns 3,433,957 shares of the medical research company’s stock valued at $652,246,000 after acquiring an additional 161,085 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of IQVIA by 22.8% in the second quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock worth $492,659,000 after acquiring an additional 581,157 shares during the period. Nordea Investment Management AB raised its holdings in shares of IQVIA by 12.3% during the third quarter. Nordea Investment Management AB now owns 2,314,219 shares of the medical research company’s stock worth $421,257,000 after purchasing an additional 253,759 shares during the last quarter. Finally, Cantillon Capital Management LLC lifted its position in IQVIA by 27.3% during the third quarter. Cantillon Capital Management LLC now owns 1,926,934 shares of the medical research company’s stock valued at $366,002,000 after purchasing an additional 413,256 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Down 4.1%

IQV stock opened at $171.21 on Wednesday. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. The firm has a 50-day simple moving average of $205.12 and a 200-day simple moving average of $207.39. The stock has a market capitalization of $29.05 billion, a P/E ratio of 21.78, a P/E/G ratio of 1.72 and a beta of 1.39.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. During the same period last year, the company posted $3.12 EPS. IQVIA’s quarterly revenue was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of analyst reports. Evercore reissued an “outperform” rating and issued a $225.00 price target on shares of IQVIA in a report on Thursday, February 5th. Truist Financial decreased their target price on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research note on Thursday, February 19th. Morgan Stanley set a $240.00 price target on shares of IQVIA in a report on Wednesday, February 11th. TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and lifted their price objective for the company from $174.00 to $213.00 in a report on Monday. Finally, Mizuho set a $215.00 price objective on shares of IQVIA in a research report on Monday, February 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $229.13.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.